MICRO-RNAs OF NEUTROPHILS IN RENAL ANTINEUTROPHIL CYTOPLASMIS ANTIBODY (ANCA) -ASSOCIATED VASCULITIS

Study Overview
=================
Brief Summary
-----------------
Activation of neutrophils by ANCA (Anti-Neutrophil Cytoplasm Antibodies) and subsequent microvascular endothelial cell damage is the main feature of ANCA-associated vasculitis (AAV), a severe autoimmune disease that often targets the kidney. There is no specific treatment for AAV to date and 25% of patients with renal damage evolve towards end-stage renal disease, requiring dialysis and kidney transplantation. In addition, there is no reliable biological marker of the disease activity available, which makes the diagnostic, follow-up and treatment of patients difficult. Therefore, the identification of new therapeutic targets and non-invasive biomarkers constitutes a major clinical challenge to improve AAV patients care and to ameliorate their renal outcome.

Official Title
-----------------
MICRO-RNAs OF NEUTROPHILS IN RENAL ANCA-ASSOCIATED VASCULITIS

Conditions
-----------------
ANCA-associated Vasculitis

Intervention / Treatment
-----------------
* Other: Non interventional study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria for patients: Adult patients aged over 18 years Patients with Granulomatosis with polyangiitis or microscopic polyangiitis meeting the criteria of Chapel Hill. corticosteroid treatment <20 mg / day. Informed consent: oral for participation in research and writing for biological collection. Inclusion Criteria for controls patients: - healthy-topics matched for age, recruited from the Etablissement français du sang or in the Department of Internal Medicine of Nantes University Hospital Non Inclusion Criteria: ANCA-associated vasculitis with Eosinophilic granulomatosis with polyangiitis (AAV-EGPA). Infectious or progressive tumor pathology. Pregnancy, lactation Treatment with cyclophosphamide in the 6 months prior to inclusion. Terminal chronic renal failure, presence of organ allograft. Thrust Patients receiving corticosteroids> 20 mg / d in the previous 4 weeks. Inability to give informed about information (subject in emergencies, understanding of the subject of difficulty, ...) Minor subject, under judicial protection, guardianship

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group AAV<br>Patients recruited from the Nantes University Hospital. 50 milliliter of blood and 10mL of urine are collected from these patients during levies in clinical visit. | Other: Non interventional study<br>* This is a non interventional study because all levies are performed during visit planned for the care of patients.<br>|
| Group control<br>People recruited from the Etablissement français du sang (French blood establishment ). 10 milliliter of blood are collected from these donors | Other: Non interventional study<br>* This is a non interventional study because all levies are performed during visit planned for the care of patients.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Expression profile of miRNAs in patients with AAV in circulating neutrophils, plasma and urine. |  | 6 month after maintenance treatment |